Compare BIO-TECHNE Corp (TECH) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs T-Mobile Us Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while T-Mobile Us Inc trades at $178.4 (market cap $191.15B). The key difference: T-Mobile Us Inc is far larger — about 17× BIO-TECHNE Corp's market cap, and T-Mobile Us Inc pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| TECH | TMUS | |
|---|---|---|
Market Cap | $11.24B | $191.15B |
Sector | Health | Media |
52-Week High | $72.29 | $259.01 |
52-Week Low | $43.31 | $167.65 |
Enterprise Value | $11.32B | $307.76B |
Dividend Yield | 0.44% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
T-Mobile US (TMUS) trades at $177.19, down 1.54% over 24 hours, amid a bearish technical signal and recent volatility. The company reported strong Q2 2026 earnings with a beat on EPS of $2.99 versus $2.59 expected, alongside revenue growth and raised cash flow guidance. However, technical indicators show selling pressure, with support at $176 and resistance at $179. Valuation metrics include a P/E of 18.53 and P/S of 2.13, while profitability remains robust with a net income margin of 11.45%.
The outlook for TMUS is mixed; strong fundamentals and an 81% analyst buy rating support upside to a $233.20 consensus target, but risks include competitive threats from SpaceX's Starlink and technical bearishness. Investors should weigh solid execution against near-term headwinds for potential long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
